Clinical Trials for Pancreas Cancer

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressive, measurable, unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior peptide receptor radionuclide therapy receive up to four doses of [212Pb]VMT-α-NET, an SSTR2-targeting radiopharmaceutical that delivers lead-212 alpha-particle radiation to tumors. IV renoprotective amino acids are given before each dose.

ClinicalTrials.gov ID: NCT05636618

Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic breast, ovarian, or prostate cancer and MRI-confirmed brain metastases receive oral DSB2455, an investigational selective PARP1 inhibitor targeting DNA-damage repair. Eligible patients must have measurable disease, ECOG performance status 0–1, and a safely accessible lesion for biopsy; prior selective PARP1 inhibition is excluded.

ClinicalTrials.gov ID: NCT06458712

An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring selected MAPK-pathway mutations, ECOG 0–1, and no suitable standard therapy receive oral IPN01194 monotherapy. IPN01194 inhibits ERK1/2, downstream components of MAPK signaling.

ClinicalTrials.gov ID: NCT06305247

A Phase 1/2a First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients with Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic solid tumors after standard therapy or without a suitable standard option receive oral CT3001 monotherapy, an investigational GPR35 inhibitor intended to suppress YAP signaling. Dose expansion is limited to patients with advanced colorectal cancer or pancreatic ductal adenocarcinoma.

ClinicalTrials.gov ID: NCT06598007

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic solid tumors across multiple cohorts (e.g., gastric/EGJ, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal SCC, Merkel cell, MMR‑deficient/MSI cancers) after standard therapy, ECOG 0–1; stable small brain mets allowed. Treatment is autologous tumor-infiltrating lymphocyte (TIL) therapy (tumor harvest → ex vivo expansion) after cyclophosphamide/fludarabine lymphodepletion, followed by high-dose aldesleukin (IL-2) to support T-cell expansion; single course with option for a second.

ClinicalTrials.gov ID: NCT03935893

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced mesothelin-associated solid tumors, ECOG performance status 0–1, and adequate organ function receive weekly intravenous CT-95 monotherapy. CT-95 is an investigational bispecific antibody that binds mesothelin on tumor cells and CD3 on T cells to promote tumor-cell killing.

ClinicalTrials.gov ID: NCT06756035

A Phase 1 Study of Gemcitabine, Nab-Paclitaxel, and Bosentan in Patients With Unresectable Pancreatic Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable pancreatic carcinoma eligible for gemcitabine plus nab-paclitaxel receive that regimen with added oral bosentan, a dual endothelin receptor antagonist intended to modulate tumor stroma and perfusion to enhance drug delivery. Key exclusions include significant neuropathy and interacting CYP3A/CYP2C9 drugs; safety, tolerability, and preliminary antitumor activity are assessed across different bosentan lead-in schedules.

ClinicalTrials.gov ID: NCT04158635

Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated TROP2-positive ovarian, fallopian tube, primary peritoneal, mesonephric-like, pancreatic ductal, or ampullary-type cancer involving the peritoneum or retroperitoneal nodes receive cyclophosphamide/fludarabine lymphodepletion followed by one intraperitoneal dose of donor cord-blood NK cells engineered to target TROP2 and express IL-15.

ClinicalTrials.gov ID: NCT05922930

A Phase 1 Dose Finding Study of the gFOLFOXIRITAX Regimen Using UGT1A1 Genotype-directed Irinotecan With Fluorouracil, Leucovorin, Oxaliplatin and Taxotere in Patients With Untreated Advanced Upper Gastrointestinal Adenocarcinomas: The I-FLOAT Study

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with untreated locally advanced or metastatic upper GI adenocarcinomas (including pancreatic, gastroesophageal, cholangiocarcinoma, gallbladder, ampullary, and select CUP) receive a multi-agent regimen of irinotecan, 5-FU/leucovorin, oxaliplatin, and docetaxel, with irinotecan dose tailored by UGT1A1 genotype. The study assesses safety, tolerability, and preliminary efficacy of this intensive first-line combination in ECOG 0–1 patients.

ClinicalTrials.gov ID: NCT04361708

A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Metastatic, treatment-naïve PDAC (ECOG 0–1) receiving first-line gemcitabine/nab-paclitaxel plus motixafortide (CXCR4 antagonist to disrupt stroma and enhance immune infiltration) and cemiplimab (PD‑1 inhibitor); requires measurable disease and biopsy-accessible tumor. Excludes prior PDAC therapy, active autoimmune disease requiring treatment, CNS mets, uncontrolled infections/hepatitis/HIV, and significant comorbidity.

ClinicalTrials.gov ID: NCT04543071